ACCESS Newswire

Music Licensing, Inc.

19.12.2022 14:02:09 CET | ACCESS Newswire | Press release

Share
Music Licensing, Inc. (OTC: SONG) Announces Major Updates for Investors: Form 211 Filing, Potential Forward Stock Split or Dividend, and Plans to List on Nasdaq

NAPLES, FL / ACCESSWIRE / December 19, 2022 / Music Licensing, Inc. (OTC PINK:SONG), owner of Pro Music Rights, one of the world's largest music licensing companies, is pleased to announce that a new Form 211 has been filed with FINRA to restore its proprietary quote eligibility. The company is now awaiting FINRA to process the form and is confident that it will fully restore its eligibility.

In addition, Music Licensing, Inc. (OTC: SONG) is exploring a forward stock split or a stock-based dividend once FINRA has processed the new Form 211. The company is considering a 1 for 5 forward stock split to increase liquidity, tighten the bid/ask spread, and increase trading volume. It is also exploring the possibility of issuing a dividend to shareholders in the form of a new class of common stock with identical rights as the current class. Music Licensing, Inc. (OTC: SONG) plans to file another Form 211 with FINRA to allow both classes of common stock to be publicly traded.

Music Licensing, Inc. (OTC: SONG) has been in communication with Nasdaq's First North Growth Market in Sweden to list on the exchange. On December 15, 2022, the company's European capital markets listing advisor, DCM Asesores, had a call with Nasdaq First North Growth Market to become a certified adviser. DCM Asesores expects to undergo training to become a certified adviser by mid to late February 2023 and guide Music Licensing, Inc. (OTC: SONG) through the listing process on Nasdaq First North Growth Market. Nasdaq has already confirmed the reservation of the symbol NASDAQ: MUSIC for Music Licensing, Inc. (OTC: SONG)'s listing.

In other news, Music Licensing, Inc. (OTC: SONG) is working with its legal counsel to collect on a judgment won against Ayujoy Herbals (OTC: AJOY) and expects to receive a response on an arbitration complaint filed with FINRA by Pro Music Rights and the Jake P. Noch Family Office seeking $386,574,108.25 plus interest and costs from OTC Link LLC by January 6, 2023.

About Pro Music Rights, Inc. (ProMusicRights.com)

Pro Music Rights the 5th public performance rights organization (PRO) ever formed in the United States. Its licensees include notable companies like TikTok, iHeart Media, Triller, Napster, 7Digital, Vevo, and hundreds of others. Pro Music Rights controls an estimated market share of 7.4% in the United States, representing over 2,500,000 works that feature notable artists such as A$AP Rocky, Wiz Khalifa, Pharrell, Young Jeezy, Juelz Santana, Lil Yachty, MoneyBaggYo, Larry June, Trae Pound, Sause Walka, Trae Tha Truth, Sosamann, Soulja Boy, Lex Luger, Lud Foe, SlowBucks, Gunplay, OG Maco, Rich The Kid, Fat Trel, Young Scooter, Nipsey Hussle, Famous Dex, Boosie Badazz, Shy Glizzy, 2 Chainz, Migos, Gucci Mane, Young Dolph, Trinidad James, Fall Out Boy, and countless others. For more information, please visit promusicrights.com.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Music Licensing, Inc. & Pro Music Rights, Inc. to accomplish its stated plan of business. Music Licensing, Inc. & Pro Music Rights, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Pro Music Rights, Inc., Music Licensing, Inc., or any other person.

Contact:
investors@ProMusicRights.com

SOURCE: Music Licensing, Inc.



View source version on accesswire.com:
https://www.accesswire.com/732278/Music-Licensing-Inc-OTC-SONG-Announces-Major-Updates-for-Investors-Form-211-Filing-Potential-Forward-Stock-Split-or-Dividend-and-Plans-to-List-on-Nasdaq

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release

ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the

Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release

HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy

Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen

Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release

HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye